What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small…”In the company’s words, NCT06447662 on ClinicalTrials.gov
- Other names
- PF-4040
Other drugs for Carcinoma, Pancreatic Ductal
- Acoustic Cluster TherapyEXACT Therapeutics AS · Phase 2
- JAB-21822Allist Pharmaceuticals · Phase 1/2
- JAB-3312Allist Pharmaceuticals · Phase 1/2
- DaraxonrasibRevolution Medicines · Phase 1/2
- RelacorilantCorcept Therapeutics · Phase 2
- ZoldonrasibRevolution Medicines · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 9 Oct 2026 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026